Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.

NCT Number	NCT06289751
Lead Sponsor	Tongji Hospital Collaborators: The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Women's Hospital School Of Medicine Zhejiang University, Southwest Hospital, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital
Conditions	Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
Enrollment	50 participants
Start Date	2024-09-03
Primary Completion	2026-03-01 (estimated)
Study Completion	2031-01-01 (estimated)
Updated on ClinicalTrials.gov	2024-09-19